Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(31)
•••
Comment by stanleyon May 24, 2012 7:04am
294 Views
Post# 19940670

RE: Can anyone assist........?? TSX Only

RE: Can anyone assist........?? TSX Only

RE: Short Position

Short History

Symbol Report Date Volume Change % of Float
BRD - T 2012-05-15 164,349 -19,954 0.08
BRD - T 2012-04-30 184,303 -127,431 0.08
BRD - T 2012-04-15 311,734 -173,957 0.14
BRD - T 2012-03-31 485,691 212,729 0.22
BRD - T 2012-03-15 272,962 -898,265 0.13
BRD - T 2012-02-28 1,171,227 795,525 0.58
BRD - T 2012-02-15 375,702 -35,252 0.19
BRD - T 2012-01-31 410,954 -1,276 0.20
BRD - T 2012-01-15 412,230 23,702 0.20
BRD - T 2011-12-31 388,528 -24,936 0.19
BRD - T 2011-12-15 413,464 49,903 0.21
BRD - T 2011-11-30 363,561 60,359 0.19
BRD - T 2011-11-15 303,202 -321 0.15
BRD - T 2011-10-31 303,523 10,044 0.15
BRD - T 2011-10-15 293,479 -27,361 0.15
BRD - T 2011-09-30 320,840 60,603 0.16
BRD - T 2011-09-15 260,237 11,300 0.13
BRD - T 2011-08-31 248,937 24,800 0.13
BRD - T 2011-08-15 224,137 29,228 0.12
BRD - T 2011-07-31 194,909 -56,567 0.10
BRD - T 2011-07-15 186,876 -34,200 0.10
BRD - T 2011-06-30 221,076 11,582 0.12
BRD - T 2011-06-15 209,494 -118,708 0.11
BRD - T 2011-05-31 328,202 47,972 0.17
BRD - T 2011-05-15 280,230 33,000 0.15
BRD - T 2011-04-30 247,230 21,800 0.13
BRD - T 2011-04-15 225,430 32,100 0.12
BRD - T 2011-03-31 193,330 -68,859 0.11
BRD - T 2011-03-15 262,189 30,832 0.14
BRD - T 2011-02-28 231,357 -91,873 0.13
BRD - T 2011-02-15 323,230 129,117 0.18
BRD - T 2011-01-31 194,113 -416,023
BRD - T 2011-01-15 610,136 202,448
BRD - T 2010-12-31 407,688 -4,841
BRD - T 2010-12-15 412,529 284,844
BRD - T 2010-11-30 127,685 -199,734
BRD - T 2010-11-15 327,419 41,804
BRD - T 2010-10-31 285,615 -2,561,729
BRD - T 2010-10-15 2,847,344 1,085,941
BRD - T 2010-09-30 1,761,403 1,549,110
BRD - T 2010-09-15 212,293 -6,683
BRD - T 2010-08-31 218,976 31,400
BRD - T 2010-08-15 187,576 -55,861
BRD - T 2010-07-31 243,437 56,083
BRD - T 2010-07-15 187,354 -1,178,549
BRD - T 2010-06-30 1,365,903 1,365,903
BRD - V 2008-11-15 -70,000
BRD - V 2008-10-31 70,000
BRD - V 2008-10-15 70,000
BRD - V 2008-09-30 70,000
BRD - V 2008-09-15 70,000
BRD - V 2008-08-31 70,000 -31,500
BRD - V 2008-08-15 101,500 31,500
BRD - V 2008-07-31 70,000
BRD - V 2008-07-15 70,000
BRD - V 2008-06-30 70,000 -400
BRD - V 2008-06-15 70,400 400
BRD - V 2008-05-31 70,000
BRD - V 2008-05-15 70,000
BRD - V 2008-04-30 70,000
BRD - V 2008-04-15 70,000 -90,000
BRD - V 2008-03-31 160,000 66,000
BRD - V 2008-03-15 94,000 -242,698
BRD - V 2008-02-29 336,698 120,698
BRD - V 2008-02-15 216,000 13,000
BRD - V 2008-01-31 203,000 -49,000
BRD - V 2008-01-15 252,000 106,000
BRD - V 2007-12-31 146,000 41,000
BRD - V 2007-12-15 105,000 -134,750
BRD - V 2007-11-30 239,750 123,000
BRD - V 2007-11-15 116,750 75,000
BRD - V 2007-10-31 41,750 41,750
BRD - V 2007-08-31 -13,000
BRD - V 2007-08-15 13,000 13,000
BRD - V 2007-05-15 -5,000
BRD - V 2007-04-30 5,000 5,000
BRD - V 2007-04-15 -7,425
BRD - V 2007-03-31 7,425
BRD - V 2007-03-15 7,425 -41,000
BRD - V 2007-02-28 48,425 -29,575
BRD - V 2007-02-15 78,000 78,000
BRD - V 2006-12-15 -5,775
BRD - V 2006-11-30 5,775 -143,675
BRD - V 2006-11-15 149,450 149,450
BRD - V 2006-06-15 -25,000
BRD - V 2006-05-31 25,000 25,000
BRD - V 1998-01-21 -4,000
BRD - V 1998-01-08 4,000 4,000
BRD - V 1997-10-07 -3,000
BRD - V 1997-09-19 3,000 3,000
BRD - V 1997-06-20 -500
BRD - V 1997-06-02 500
BRD - V 1997-05-14 500 500

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities